Breaking News

PCI Pharma Services Acquires Bellwyck

Expands global reach in key markets, adds four GMP facilities to PCI’s network

By: Kristin Brooks

Managing Editor, Contract Pharma

PCI Pharma Services (PCI), a pharma and biopharma global supply chain solutions provider, acquired Bellwyck Pharma Services, headquartered in Toronto, Canada. Bellwyck is a provider of primary and secondary packaging and labeling for clinical trial and commercial drug markets. The acquisition will add four GMP-compliant facilities to the PCI network in the U.S., Germany and Canada. PCI is headquartered in Philadelphia, PA.

Bellwyck’s clinical and commercial supply chain solutions complement PCI’s existing core capabilities including clinical trial packaging, labeling and logistics for Phase I-IV studies as well as full-service commercial packaging. With the addition of Bellwyck, PCI will now have 25 GMP facilities across North America, Europe, and Asia-Pacific, employing over 3,700 highly trained associates.

“We are thrilled to welcome the Bellwyck team into the PCI family,” said Salim Haffar, chief executive officer, PCI Pharma Services. “Their passion for patients, talented team and innovative approach to client challenges is perfectly aligned to our purpose and global strategy as PCI strives to be the bridge between life-changing therapies and patients around the world. We are particularly excited that this acquisition will expand our clinical business worldwide and provide our clients with access to sites in continental Europe and Canada, in addition to our existing facilities.”

“We are delighted that Bellwyck is joining the PCI team and anticipate a seamless integration for our employees and clients,” said Jeff Sziklai, chief executive officer, Bellwyck Pharma Services. “We have a shared focus on innovation, quality, exceptional service and our employees. Joining forces with a global industry leader, such as PCI, is a great step forward for Bellwyck. We look forward to helping accelerate the global growth of PCI’s clinical business, leveraging our reputation for innovative, customized clinical trial solutions for our clients.”

Bellwyck is PCI’s third acquisition outside of the U.S. in three years, and is part of PCI’s geographic expansion efforts.


Keep Up With Our Content. Subscribe To Contract Pharma Newsletters